Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $6.2

Benzinga · 04/15 09:52
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $6.6 to $6.2.